We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Copy Control 9 (CC9)
Copy Control 3 (CC3)
* Panel makeup subject to change
Several recurrent and prognostic chromosome alterations have been identified in myeloma and their identification is useful in the management of these patients. These include translocations involving the FGFR3, MAF, MAFB and CCND1 genes with the IGH gene, loss of 17p13.1(P53), loss of 13q14.3, rearrangement of MYC, and hyperdiploidy. The t(14;16), t(4;14), and t(14;20) translocations involving the MAF, FGFR3, and MAFB genes, respectively, each independently identify poor prognostic groups. Deletion of 13q14.3, rearrangement of MYC, or 17p13.1(P53) are two additional poor prognostic indicators in myeloma. Hyperdiploidy is associated with a favorable prognosis and the t(11;14) portends an intermediate prognosis.
Disease State: Plasma Cell Myeloma/Neoplasm
CPT Code(s): 88374x6, 88367; 88373x5 (reference only; panel run as algorithm; CPTs may vary)
Turnaround Time: Within 3-4 business days of receipt
Schedule: Monday - Friday
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR -
• Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR -
• Fresh tissue in RPMI